Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued a press release on October 29, 2026, announcing that it will release its third-quarter 2026 financial results after market close on November 5, 2026, followed by a conference call at 2:00 p.m. Pacific Time.

Key Highlights

  • Results date: Third-quarter 2026 financial results will be released after market close on Thursday, November 5, 2026.
  • Period covered: The quarter ended September 30, 2026.
  • Conference call time: A call to discuss results is scheduled for 2:00 p.m. Pacific Time on November 5, 2026.
  • Webcast replay: According to the filing, a webcast replay will be available on the company's investor page within 24 hours after the live call ends.
  • Company focus: Amphastar describes itself as a biopharmaceutical company that develops, manufactures, and commercializes generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient products.

Amphastar's Q3 2026 Earnings Date and Business Context

According to the announcement, Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, will publish its financial results for the three months ended September 30, 2026, after U.S. equity markets close on November 5, 2026. The filing states that a conference call will follow at 2:00 p.m. Pacific Time, providing management the opportunity to discuss the reported figures.

The filing describes Amphastar as a biopharmaceutical company that concentrates on technically challenging generic and proprietary products across injectable, inhalation, and intranasal delivery forms, and that also sells active pharmaceutical ingredient products. The company's finished goods are distributed primarily through group purchasing organizations, drug wholesalers, and drug retailers, according to the disclosure. Named product brands referenced in the filing include BAQSIMI, Primatene MIST, Amphadase, and Cortrosyn.

The press release contains forward-looking statements regarding future financial performance, product development timelines, FDA filing or approval timing, product launches, and related business matters. The filing states that these statements "are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections," and it identifies risks detailed in Amphastar's Annual Report on Form 10-K for the year ended December 31, 2025, filed February 26, 2026, as well as subsequent quarterly reports. The company states it "undertakes no obligation to revise or update" such statements.

What Was Disclosed

Amphastar Pharmaceuticals announced the date and time of its third-quarter 2026 earnings release and accompanying conference call. The company also provided a brief description of its business operations and included forward-looking statement cautionary language referencing prior regulatory filings.